CAPA Regimen Shows Promise for NKTCL

A Phase 2 clinical trial shows that the CAPA regimen, combined with radiotherapy, is highly effective for treating early-stage extranodal natural killer/T-cell lymphoma. The treatment demonstrated high survival rates with fewer severe blood-related side effects than traditional chemotherapy.
Why it matters
This study offers a promising, less toxic alternative for treating a rare and aggressive form of lymphoma.
CAPA followed by radiotherapy achieved high response rates and promising survival outcomes in patients with early-stage extranodal natural killer/T-cell lymphoma (NKTCL), according to a multicentre Phase 2 trial. The chemotherapy-sparing approach was also associated with relatively low rates of severe haematological toxicity, addressing a challenge associated with conventional asparaginase-based chemoradiotherapy.
The trial investigated whether induction treatment with camrelizumab, low-dose apatinib, and pegaspargase (CAPA), followed by sequential radiotherapy, could provide effective disease control while reducing blood-related complications.
Adults with biopsy-confirmed nasal or upper aerodigestive tract NKTCL at Lugano Stage I or II received four 21-day cycles of CAPA, followed by intensity-modulated radiotherapy at a dose of 50–56 Gy. The primary endpoint was complete response at week 24, assessed using Lugano 2014 criteria.
Between June 2020 and October 2022, 61 patients received CAPA. Of these, 54 (88.5%) had evaluable assessments at week 24.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in